César Molinero

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Olga Salamero, Pau Montesinos, Christophe Willekens et al. · Journal of Clinical Oncology · 2020 · 101 citations · Full text

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim C. P. Somervaille, Olga Salamero, Pau Montesinos et al. · Blood · 2016 · 41 citations

First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat

Rosa María Antonijoan, J.M. Ferrero-Cafiero, Jimena Coimbra et al. · CNS Drugs · 2021 · 18 citations · Full text

[P4–576]: FIRST‐IN‐HUMAN PHASE I RESULTS SHOW SAFETY, TOLERABILITY AND BRAIN PENETRANCE OF ORY‐2001, AN EPIGENETIC DRUG TARGETING LSD1 AND MAO‐B

Tamara Maes, César Molinero, Rosa Antonijoan et al. · Alzheimer s & Dementia · 2017 · 13 citations

Epigenetic Change, Psychopharmacology, Pharmacotherapy +18